Clinical trial · Interventional
PMRR-NO: Pulmonary Metabolic Radiation Response Versus Exhaled Nitric Oxide
A Biomarker Study Comparing the Pulmonary Metabolic Radiation Response Versus Exhaled Nitric Oxide in Patients Who Receive Thoracic Radiotherapy
NCT00867477CI-TRIAL-00015488completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical research study is to use a new breathing test that measures the amount of nitric oxide (NO) you exhale. Researchers want to compare your "NO" levels to the amount of inflammation in your lungs, as measured using a positron emission tomography (PET) scan reading, and with respiratory symptoms questionnaire.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
| Gastrointestinal Disease | — | UNRESOLVED | — |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Breathing Test | Procedure | — | UNRESOLVED |
| Pet Scan | Procedure | — | UNRESOLVED |
| Respiratory Symptoms Questionnaire | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Cohort 1: Esophagus Cancer
- description
- Breathing Test + Respiratory Symptoms Questionnaire
- interventionNames
- Procedure: Breathing Test
- Behavioral: Respiratory Symptoms Questionnaire
- type
- EXPERIMENTAL
- label
- Cohort 2: Lung Cancer
- description
- Breathing Test + Respiratory Symptoms Questionnaire
- interventionNames
- Procedure: Breathing Test
- Behavioral: Respiratory Symptoms Questionnaire
- Procedure: Pet Scan
Primary outcomes (1)
- measure
- Comparison Patient's PMRR + Mean Exhaled NO Measurement
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Patients with pathologic diagnosis of esophagus cancer. 2. For the cohort 2, patients with the pathological diagnosis of lung cancer. 3. For the cohort 3, patients with any pathological diagnosis of a thoracic malignancy. 4. Patients must sign informed consent. 5. Patients who will receive concurrent chemotherapy and radiation therapy will be undergoing PET-scan for restaging between 25 and 75 days after radio therapy. 6. For Lung Cohort, patients who will receive concurrent chemotherapy and radiation therapy or greater or equal to 3 weeks of radiation therapy alone. 7. For the Lung Cohort, participation in a PET-scan for restaging between 40-50 days after radiotherapy is required. 10 patients will receive a second PET-scan within 2-7 days as a test for reproducibility. Exclusion Criteria: 1. Significant pleural effusion as evaluated by the attending Radiation Oncologist is excluded. 2. Patients who received thoracic radiotherapy prior to the study.
References
Publications (0)
Data not yet available
No reference posted for this study.